Perspective Therapeutics (CATX) Accumulated Expenses (2011 - 2026)

Perspective Therapeutics (CATX) has 16 years of Accumulated Expenses data on file, last reported at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 33.1% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (up 33.1% YoY), and the FY2025 full-year result was $7.5 million, up 36.71% from the prior year.
• Accumulated Expenses retreated to $3.9 million in Q1 2026, from $7.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $7.5 million in Q4 2025 to a low of $150000.0 in Q2 2022.
• A 5-year average of $2.7 million and a median of $2.6 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses declined 10.04% in 2022 and surged 1439.91% in 2023, its largest moves.
• Tracing CATX's Accumulated Expenses over 5 years: stood at $233000.0 in 2022, then surged by 1439.91% to $3.6 million in 2023, then surged by 52.68% to $5.5 million in 2024, then soared by 36.71% to $7.5 million in 2025, then slumped by 48.24% to $3.9 million in 2026.
• Business Quant data shows CATX's Accumulated Expenses at $3.9 million in Q1 2026, $7.5 million in Q4 2025, and $6.7 million in Q3 2025.